Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As I posted last week, I what I saw on my charts is going to send this to Mars BOOM! ALL MY CUSTOM INDICATORS SHOW $6/7 NEXT WEEK IF NOT TOMORROW
Big $$ hitting, shorts are about to get rocked here...
This stock comes from the same company that recommended BOXL two weeks ago. AIM has a lot more to go.
I warned you shorting pre market manipulaors that you were going to get played after the open, you had it coming to you with your little games of manipulation premarket
short trading manipulaors have been identified on three different Twitter trading blogs as those trying to create a pull back in price premarket to cover short positions after they shorted at over $3.10 yesterday, one of the trading blogs with over 10K followers says he's buying any pull back after the open and recommend that his followers do the same, sounds like shorts getting setup to get squeezed if they don't cover out of the gate.
I told y'all this jump was gonna happen last week.
Banking nothing now, could be a big gapper tomorrow morning, Rob and his hoods probably are now in and adding more shares and always run them up big the next day, stupid foolish shorts could end up drowning in I sea red tomorrow.
Wrong board dude, this is a real stock, can't say much about the one youy talking about.
News: $AIM Atalaya Mining PLC Announces Q2 2020 Operations Update
NICOSIA, CYPRUS / ACCESSWIRE / July 15, 2020 / Atalaya Mining Plc (AIM:ATYM)(TSX:AYM) is pleased to announce its operations update for the second quarter of 2020 ("Q2 2020"). Operating Highlights Proyecto Riotinto Q2 2020 copper production was a new record of 13,635 tonnes, represe...
Read the whole news AIM - Atalaya Mining PLC Announces Q2 2020 Operations Update
$aim monster day from our call hope y’all banking
Like GE ) N .e , and could be the next big runner, like that one which is now up over 300% today.
Aim big volume today small float took a starter. Let’s see what happens
AIM...$2.85 in the P/M...AIM been looking like she wants to breakout lately...imo...we shall see...
[7:13 AM]
georgie1806/25/2020
AIM...$2.58...A/H...Breakout setting up here ...imo...we shall see...
Pre-market rally. Now this is what we have been waiting for. BOOOOM!!
I am seeing a lot of after hours activity. ***Alert***
The Bollinger Bands are tight... which means we have a big move coming soon as tomorrow!!!!!!!!!!!!!!!!!!!!!!! I think we are going up big time...
I am thinking we see $6/$7 dollars or higher this month.
$aim $2.43 v -0.01 (-0.41%)
Volume: 1,811,329 @07/02/20 8:00:00 PM EDT
$AIM this is good AIM ImmunoTech Added to Russell Microcap(R) Index
ACCESSWIRE ACCESSWIRE•June 29, 2020
https://finance.yahoo.com/news/aim-immunotech-added-russell-microcap-105500883.html
OCALA, FL / ACCESSWIRE / June 29, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that it has been added to the Russell Microcap® Index, following the annual Russell indexes reconstitution, effective after the market open on June 29, according to a final list of additions posted on June 26.
[ https://aimimmuno.com/all-articles/ ]
Annual Russell indexes reconstitution captures the 4,000 largest US stocks, ranking them by total market capitalization.
Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.
FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
Tom Equels, CEO of AIM ImmunoTech, commented "This addition to the Russell Microcap® Index reflects our progress as we continue to advance both our COVID-19 and oncology programs.
Inclusion in the Russell Microcap® Index should also help increase our exposure within the global investment community as we continue to execute on important milestones."
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
Approximately $9 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider. For more information on Russell Microcap® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers.
AIM's flagship products include the
Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®.
Based on results of published, peer-reviewed pre-clinical studies and clinical trials,
AIM believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties.
Clinical trials of Ampligen® include studies of cancer patients with renal cell carcinoma,
malignant melanoma,
colorectal cancer,
advanced recurrent ovarian cancer and
triple negative metastatic breast cancer.
These and other potential uses will require additional clinical
trials to confirm the safety and effectiveness data necessary to
support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important
debilitating diseases and disorders of the immune system.
The Company is also advancing Ampligen® as a potential treatment
for COVID-19, the disease caused by the SARS-CoV-2 coronavirus,
and believes Ampligen® has significant therapeutic potential as both
an early-onset treatment and prophylaxis against this new and deadly virus.
The U.S. Food and Drug Administration has authorized the first human trial assessing the safety and effectiveness of
Ampligen® in combination with interferon alfa-2b,
in cancer patients with COVID-19.
About FTSE Russell
FTSE Russell is a leading global index provider creating and managing a wide range of indexes, data and analytic solutions to meet client needs across asset classes, style and strategies. Covering 98% of the investable market, FTSE Russell indexes offer a true picture of global markets, combined with the specialist knowledge gained from developing local benchmarks around the world.
FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $16 trillion is currently benchmarked to FTSE Russell indexes.
For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create investment funds, ETFs, structured products and index-based derivatives.
FTSE Russell indexes also provide clients with tools for asset allocation, investment strategy analysis and risk management.
A core set of universal principles guides FTSE Russell index design
and management: a transparent rules-based methodology is informed by independent committees of leading market participants.
FTSE Russell is focused on index innovation and customer partnership applying the highest industry standards and embracing the IOSCO Principles. FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit http://www.ftserussell.com.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. Any forward-looking statements set forth herein speak only as of the date of this press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The information found on our website is not incorporated by reference herein and is included for reference purposes only.
Contact:
Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com
SOURCE: AIM ImmunoTech Inc.
View source version on accesswire.com:
https://www.accesswire.com/595266/AIM-ImmunoTech-Added-to-Russell-MicrocapR-Index
AIM ImmunoTech Inc (AIM)
2.4701 ? -0.0899 (-3.51%)
Volume: 719,063 @06/30/20 9:52:58 AM EDT
Bid Ask Day's Range
- - 2.4 - 2.5
AIM Detailed Quote
$AIM #2 this is good AIM ImmunoTech Added to Russell Microcap(R) Index
ACCESSWIRE ACCESSWIRE•June 29, 2020
https://finance.yahoo.com/news/aim-immunotech-added-russell-microcap-105500883.html
OCALA, FL / ACCESSWIRE / June 29, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that it has been added to the Russell Microcap® Index, following the annual Russell indexes reconstitution, effective after the market open on June 29, according to a final list of additions posted on June 26.
[ https://aimimmuno.com/all-articles/ ]
Annual Russell indexes reconstitution captures the 4,000 largest US stocks, ranking them by total market capitalization.
Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.
FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
Tom Equels, CEO of AIM ImmunoTech, commented "This addition to the Russell Microcap® Index reflects our progress as we continue to advance both our COVID-19 and oncology programs.
Inclusion in the Russell Microcap® Index should also help increase our exposure within the global investment community as we continue to execute on important milestones."
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
Approximately $9 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider. For more information on Russell Microcap® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers.
AIM's flagship products include the
Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®.
Based on results of published, peer-reviewed pre-clinical studies and clinical trials,
AIM believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties.
Clinical trials of Ampligen® include studies of cancer patients with renal cell carcinoma,
malignant melanoma,
colorectal cancer,
advanced recurrent ovarian cancer and
triple negative metastatic breast cancer.
These and other potential uses will require additional clinical
trials to confirm the safety and effectiveness data necessary to
support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important
debilitating diseases and disorders of the immune system.
The Company is also advancing Ampligen® as a potential treatment
for COVID-19, the disease caused by the SARS-CoV-2 coronavirus,
and believes Ampligen® has significant therapeutic potential as both
an early-onset treatment and prophylaxis against this new and deadly virus.
The U.S. Food and Drug Administration has authorized the first human trial assessing the safety and effectiveness of
Ampligen® in combination with interferon alfa-2b,
in cancer patients with COVID-19.
About FTSE Russell
FTSE Russell is a leading global index provider creating and managing a wide range of indexes, data and analytic solutions to meet client needs across asset classes, style and strategies. Covering 98% of the investable market, FTSE Russell indexes offer a true picture of global markets, combined with the specialist knowledge gained from developing local benchmarks around the world.
FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $16 trillion is currently benchmarked to FTSE Russell indexes.
For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create investment funds, ETFs, structured products and index-based derivatives.
FTSE Russell indexes also provide clients with tools for asset allocation, investment strategy analysis and risk management.
A core set of universal principles guides FTSE Russell index design
and management: a transparent rules-based methodology is informed by independent committees of leading market participants.
FTSE Russell is focused on index innovation and customer partnership applying the highest industry standards and embracing the IOSCO Principles. FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit http://www.ftserussell.com.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. Any forward-looking statements set forth herein speak only as of the date of this press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The information found on our website is not incorporated by reference herein and is included for reference purposes only.
Contact:
Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com
SOURCE: AIM ImmunoTech Inc.
View source version on accesswire.com:
https://www.accesswire.com/595266/AIM-ImmunoTech-Added-to-Russell-MicrocapR-Index
$AIM this is good AIM ImmunoTech Added to Russell Microcap(R) Index
ACCESSWIRE ACCESSWIRE•June 29, 2020
https://finance.yahoo.com/news/aim-immunotech-added-russell-microcap-105500883.html
https://aimimmuno.com/all-articles/
Just sit back and let the whales arrive, they will start feeding this next week.
$AIM Share Statistics;Shares Outstanding 32.62M, Float 28.77M
Avg Vol (3 month) 3 4.41M
Avg Vol (10 day) 3 4.42M
Shares Outstanding 5 32.62M
Float 28.77M
% Held by Insiders 1 2.00%
% Held by Institutions 1 2.10%
Shares Short (Jun 15, 2020) 4 1.99M
Short Ratio (Jun 15, 2020) 4 0.52
Short % of Float (Jun 15, 2020) 4 6.17%
Short % of Shares Outstanding (Jun 15, 2020) 4 6.09%
Shares Short (prior month May 15, 2020) 4 1.38M
$AIM Stock Price History
Beta (5Y Monthly) -0.91
52-Week Change 3 -38.69%
S&P500 52-Week Change 3 1.51%
52 Week High 3 7.1100
52 Week Low 3 0.3800
50-Day Moving Average 3 2.5215
200-Day Moving Average 3 1.8087
$AIM Balance Sheet;Book Value Per Share (mrq) $2.14
Total Cash (mrq) 28.09M
Total Cash Per Share (mrq) 0.96
Total Debt (mrq) 6.61M
Total Debt/Equity (mrq) 18.82
Current Ratio (mrq) 42.26
Book Value Per Share (mrq) 2.14
$AIM GREAT BALLS OF FIRE !!!!!
I like this forecast. Thank you!
$AIM DOE RE ME, AIM ImmunoTech Inc. (formerly, Hemispherx Biopharma, Inc.) previously entered into an Equity Distribution Agreement with Maxim Group LLC, or Maxim, relating to the sale of our common stock, par value $0.001 per share, of which we have sold $31,511,257 worth of shares pursuant to prospectus supplements dated July 22, 2019, March 3, 2020 and March 10, 2020 (and of which we may sell an additional $1,406,552 worth of shares as of the date hereof pursuant to the prospectus supplement dated March 10, 2020). In accordance with the terms of the Equity Distribution Agreement, as of the date hereof, we are offering additional shares of our common stock having an aggregate offering price of up to $19,406,552 from time to time through Maxim acting as agent. This prospectus supplement is being filed for the offer and sale of an additional $18,000,000 worth of shares pursuant to the Equity Distribution Agreement.
Sales of our common stock, if any, under this prospectus supplement and the accompanying base prospectus will be made in sales deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on or through the NYSE American, the existing trading market for our common stock, sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or any other method permitted by law, including in privately negotiated transactions. Maxim will use its commercially reasonable efforts to sell on our behalf all the shares of common stock requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between Maxim and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. We provide more information about how the shares of common stock will be sold in the section entitled “Plan of Distribution.”
Maxim will be entitled to compensation at a fixed commission rate of 3.5% of the gross proceeds of each sale of shares of our common stock. In connection with the sale of shares of our common stock on our behalf, Maxim will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Maxim will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Maxim with respect to certain liabilities, including liabilities under the Securities Act.
Our common stock is traded on The NYSE American under the symbol “AIM.” On June 12, 2020, the last reported sale price of our common stock was $2.59 per share.
Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page S-9 of this prospectus supplement, page 4 of the accompanying base prospectus and under similar headings in the documents incorporated by reference into this prospectus supplement and the accompanying base prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying base prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
Maxim Group LLC
The date of this prospectus supplement is June 15, 2020
GOOD MORNING THANK YOU
RE;
Robin Hood investors increased 596 in the last couple of days. They seem to sense when a run is coming as well as help produce runs.
$AIM IF JAPAN GETS GOOD RESULTS THIS COULD FLY !!!!! SHOULD BE COMING SOON !!!!!
$AIM interesting drug cures all !!!!!
quote from stock twit board
$AIM
if Roswell PRs on this trial saying Ampligen has shown to be effective and safe in cancer patients with COVID-19 that these trials will be implemented in mass quantities in several countries. An EUA will be granted by the FDA...remember the 2 drugs that have already received it, which would you rather have if you were a 75 year old COVID-19, cancer and diabetic patient? Would you choose Remdesivir? How about hydroxychloroquine? Or Ampligen that has already been deemed safe and effective on the “train wreck COVID-19 cases”. Equels mentioned in May that the Roswell COVID-19 trials were a nice surprise. AIM didn’t do anything to initiate this which tells me Roswell already knows it’s effective and they stumbled across it by accident.
Equels has said in April interview that, “Ampligen could be the only effective treatment for SARS-CoV-2.”
Key takeaway as a shareholder, read the PR before you set a PT to sell at. If Roswell says it works our micro cap will become a mid cap!
Robin Hood investors increased 596 in the last couple of days. They seem to sense when a run is coming as well as help produce runs.
Thanks for all the dd mick. Some I had forgotten. Very looking forward to Monday
Thanks for the update bud.
$AIM AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic We recently announced the AIM ImmunoTech team is working [...]
$AIM AIM ImmunoTech Reaches Deal with Japan’s National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus
AIM ImmunoTech Reaches Deal with Japan's National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus On March 9 th we announced that Japan’s National Institute of Infectious [...]
$AIM OCALA, FL / ACCESSWIRE / March 9, 2020 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that the National Institute of Infectious Diseases (NIID) in Japan will begin testing AIM's drug Ampligen as a potential treatment for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The experimental program will be conducted at both the NIID and the University of Tokyo.
The testing and research are being conducted by Hideki Hasegawa, MD, PhD, Director of the NIID's Influenza Virus Research Center, and Director of the World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza, Tokyo and Takeshi Ichinohe, PhD, Department of Pathology at the NIID, Department of Biological Science and Technology, Tokyo University of Science.
"As we have been saying all along, this emerging pandemic is caused by a virus that has nearly identical regulatory RNA sequences to the original SARS coronavirus, known as SARS-CoV-1, in respect to pathogenesis. This means that the prior studies of Ampligen in SARS-CoV-1 animal experimentation may predict similar protective effects against the new virus. The WHO has recently renamed this emerging, highly pathogenic virus as SARS-CoV-2," said AIM CEO Thomas K. Equels. "Ampligen had excellent antiviral activity against the earlier SARS coronavirus in U.S. National Institutes of Health-contracted animal experiments. In those studies of SARS-infected mice, Ampligen stands out as the only drug tested that conferred a significant survival effect: 100% of the Ampligen-treated mice survived, while none of the untreated mice survived. Because SARS-CoV-2 shares many critical similarities with SARS-CoV-1, Ampligen may have an important role to play in developing a protective early-onset therapy for this new highly pathogenic coronavirus in humans, where currently there is no known effective therapy. We are proud to work with Japan's universally esteemed NIID in the battle to curb this emerging potential pandemic."
Ampligen has established itself as a broad-spectrum antiviral with an extremely well-developed safety profile (See: "Ampligen as an Antiviral," safety slides 7-15, at https://aimimmuno.com/events-presentations/).
AIM will provide stockholders and the market with updates on results as they are available.
Referenced NIH-contracted studies of Ampligen versus SARS:
Day 2009: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787736/
Barnard 2006: https://journals.sagepub.com/doi/abs/10.1177/095632020601700505
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. AIM's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, AIM believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. These and other potential uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. For example, significant additional testing and trials will be required to determine whether Ampligen will be effective in the treatment of COVID-19 in humans and no assurance can be given that it will be the case. No assurance can be given that future studies will not result in findings that are different from those reported in the referenced studies. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. We cannot assure that our potential foreign operations will not be adversely affected by these risks. With regard to the Company's activities with Ampligen generally, no assurance can be given as to whether current or planned trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. In addition, initiation of planned clinical trials may not occur secondary to many factors including lack of regulatory approval(s) or lack of study drug. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Any forward-looking statements set forth herein speak only as of the date of this press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The information found on our website is not incorporated by reference herein and is included for reference purposes only.
Contacts:
Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com
AIM ImmunoTech Inc
Phone: 800-778-4042
Email: IR@aimimmuno.com
SOURCE: AIM ImmunoTech Inc
View source version on accesswire.com:
https://www.accesswire.com/579582/AIM-ImmunoTechs-Drug-Ampligen-to-Be-Tested-by-Japans-National-Institute-of-Infectious-Diseases-as-a-Potential-Treatment-for-the-New-SARS-Coronavirus-SARS-CoV-2-Responsible-for-the-New-Human-Infectious-Disease-COVID-19
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/15/2020 5:02:00 PM
AIM ImmunoTech Inc (AIM)
2.71 ? 0.21 (8.40%)
Volume: 12,201,777 @06/26/20 5:10:00 PM EDT
Bid Ask Day's Range
- - 2.47 - 2.83
AIM Detailed Quote
* * $AIM Video Chart 06-26-2020 * *
Link to Video - click here to watch the technical chart video
Followers
|
57
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2072
|
Created
|
04/27/12
|
Type
|
Free
|
Moderators |
AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers,
as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids
and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.
AIM ImmunoTech’s flagship products include Ampligen® (Rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon Alfa-N3).
Ampligen® represents an RNA being developed for globally important cancers, viral diseases and disorders of the immune system.
Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina.
Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory (resistant to other treatment)
or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older.
We operate a 30,000 sq. ft. facility in New Brunswick, NJ with the objective of producing Ampligen® and Alferon®.
We are committed to a focused business plan oriented toward finding senior co-development partners with the capital and
expertise needed to commercialize the many potential therapeutic aspects of Ampligen® and our FDA-approved drug Alferon® N.
April 4th, 2019
CEO Roadshow Interviews Hemispherx Thomas K. Equels Hemispherx CEO Thomas K. Equels recently sat down with Mike Elliot of CEO Roadshow to provide an update on everything the company is working at [...]
March 25th, 2019
Introducing You to the First Ampligen Quarterly Update Today we announced significant progress in our Ampligen pancreatic cancer program and our multiple Ampligen plus checkpoint blockade immuno-oncology programs. We also announced the [...]
March 9th, 2020
AIM ImmunoTech Reaches Deal with Japan's National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus
On March 9 th we announced that Japan’s National Institute of Infectious [...]
https://aimimmuno.com/all-articles/
AIM ImmunoTech Describes Their Approach and Progress with Ampligen to Combat COVID-19 SNNLive caught up with Thomas Equels, CEO AIM ImmunoTech Inc. Watch the full video here. [...]
AIM ImmunoTech Announces the National Cancer Institute's Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers We recently announced [...]
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic We recently announced the AIM ImmunoTech team is working [...]
AIM ImmunoTech Reaches Deal with Japan's National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus On March 9 th we announced that Japan’s National Institute of Infectious [...]
Ampligen® represents an RNA being developed for globally important cancers, viral diseases and disorders of the immune system.
Ampligen® has in the clinic demonstrated the potential for standalone efficacy in a number of solid tumors.
We have also seen success in increasing survival rates and efficacy in the treatment of animal tumors when
Ampligen® is used in combination with checkpoint blockade therapies.
This success in the field of immuno-oncology has guided our focus toward the potential use of Ampligen®
as a combinational therapy for the treatment of a variety of solid tumor types.
There are currently multiple Ampligen® clinical trials — both underway and planned — at major cancer research centers around the country.
Ampligen ® is also being used as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP)
approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center.
Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). AIM ImmunoTech
is currently sponsoring an expanded access program (EAP) for ME/CFS patients in the U.S.
In August 2016, we received approval of our NDA from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT)
for commercial sale of Ampligen® in the Argentine Republic for the treatment of severe CFS. With regulatory approval in Argentina,
Ampligen® is the world’s only approved therapeutic for ME/CFS.
We continue to pursue our Ampligen New Drug Application, or NDA, for the treatment of CFS with the Food and Drug Administration, or FDA.
Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina.
Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory
(resistant to other treatment) or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older.
Certain types of human papilloma viruses cause GW. AIM ImmunoTech also has approval from ANMAT for the treatment of
refractory patients that failed or were intolerant to treatment with recombinant interferon in Argentina.
We have developed and, with proper funding, will be seeking FDA Pre-Approval Inspection of a high-volume, high-efficiency,
upgraded manufacturing process to allow for the commercial viability of Alferon®.
Pipeline
https://aimimmuno.com/pipeline/
Please direct your inquiries regarding business development and licensing opportunities to: info@AIMImmunoTech.com
2117 SW Highway 484
Ocala, FL 34473
Book/sh | 1.96 |
Cash/sh | 0.84 |
Debt/Eq | 0.19
|
Shs Outstand | 32.62M |
Shs Float | 28.77M |
Short Float | 5.87% |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |